Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-TNF naïve and anti-TNF exposed IBD patients.
Vedolizumab has demonstrated efficacy and safety in patients with Crohn's disease (CD) and ulcerative colitis (UC). Endoscopic outcome data are limited, especially in anti-TNF naïve patients. The present study compared endoscopic outcome in anti-TNF naïve and exposed patients, and explored if this was affected by drug exposure. We retrospectively analysed all patients initiating vedolizumab at our tertiary referral centre since 2015. For UC, endoscopic improvement was defined as a Mayo endoscopic subscore ≤1 at week 14. For CD, endoscopic remission was defined as absence of ulcerations at week 22. Vedolizumab trough concentrations were measured at week 6, week 14 and during maintenance. A total of 336 patients were identified (53.3% CD), 20% of them were anti-TNF naïve. Endoscopic improvement was achieved by 56.1% of UC patients and endoscopic remission by 39.1% of CD patients. Endoscopic outcomes were significantly better in anti-TNF naïve vs exposed patients (all 67.2% vs 42.0%, p=0.0002; UC 74.4% vs 50.0%, p=0.02; CD: 57.1% vs 35.8%, p=0.03). Achievement of endoscopic endpoints significantly impacted long-term treatment continuation (p=9.7x10-13). A better endoscopic outcome was associated with significant higher drug exposure in both CD and UC. The results of this observational, single-centre real-life study suggest that vedolizumab may induce endoscopic remission in both CD and UC. Although anti-TNF naïve patients had a significantly better outcome, 42% of anti-TNF exposed patients still benefited endoscopically. A clear exposure-endoscopic response relationship exists, however not all patients will benefit from treatment intensification. Hence, predictive biomarkers will remain necessary.